BioinvestGPT

BioinvestGPT ApS · Research use only

NCT04867616 (Bepranemab in Alzheimer's Disease): BVCT ex-ante prediction vs. reported outcome

On 26 Apr 2024, BioinvestGPT's BVCT predicted technical partial success and commercial failure for this trial. The 31 Oct 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT04867616
Acronym
TOGETHER
Drug Name
Bepranemab
Drug MoA
anti-tau mAb inhibitor
Drug Modality
monoclonal antibody
Drug Class
First-In-Class
Therapeutic Area
Nervous System Diseases
Indication
Alzheimer's Disease
Human Patients
466
Sponsor
UCB Biopharma
Phase
Phase 2

Prediction of , index 1569

Prospective Prediction
Prediction Index
1569
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit with inferior-to-donanemab/lecanemab in CDR-SB for early AD patients)
Technical Prediction
partial SUCCESS (statistically maybe significant yet very weak clinical benefit in CDR-SB for early AD patients)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
188 days in advance
Readout Data Interpretation
Bepranemab did not meet the primary efficacy endpoint CDR-SB.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer's Disease (AD), Followed by an Open-Label Extension Period
Phase
Phase 2
Status
Completed
Enrollment
466
Lead sponsor
UCB Biopharma SRL
Conditions
Alzheimer's Disease
Interventions
OTHER: Placebo; BIOLOGICAL: Bepranemab
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2021-06-09
Primary completion
2024-05-24
Completion
2025-08-01
Primary outcomes
  • Change from Baseline to Week 80 in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) total score (From from Baseline to Week 80)

NCT04867616 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials